GW Pharmaceuticals’ shares rose more than 130% after the firm said its cannabis-derived drug for children with severe epilepsy significantly reduced the number of seizures they suffered, paving the way for the first-ever U.S. approval of a drug of its kind.
from WSJ.com: US Business http://ift.tt/24ZORAI
via IFTTT
No comments:
Post a Comment